ALBO stock forecast
Our latest prediction for Albireo Pharma, Inc.'s stock price was made on the Nov. 13, 2018 when the stock price was at 24.94$.
In the short term (2weeks), ALBO's stock price should outperform the market by 2.95%. During that period the price should oscillate between -7.93% and +11.86%.
In the medium term (3months), ALBO's stock price should outperform the market by 2.70%. During that period the price should oscillate between -17.67% and +30.40%.
Get email alertsAbout Albireo Pharma, Inc.
Albireo Pharma, Inc. is a pharmaceutical company, which engages in the development and commercialization of bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its product pipeline includes A4250, Elobixibat, and A3384. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.
At the moment the company generates 12M USD in revenues.
On its last earning announcement, the company reported a loss of -3.12$ per share.
The book value per share is 12.49$
Three months stock forecastNov. 13, 2018
Financials
| Revenue USD | Gross Margin | Operating Income | Operating Margin | Net Income | Earnings Per Share | Dividends | Payout Ratio | Shares | Book Value Per Share | Operating Cash Flow | Cap Spending | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12M | - | -33M | -268.30% | -35M | -3.12 | - | - | 11M | 12.49 | -25M | - | -25M |